Zim Laboratories

Who are in the management team of Zim Laboratories?

As of March 2023, the management team of Zim Laboratories includes Anwar S Daud (Chairman & Managing Director), Zulfiquar M Kamal (Director of Finance), Prakash Sapkal (Director of Operations), Niraj Dhadiwal (Director of Business Development), and several independent and non-executive directors. They oversee the company's operations and strategic direction.

As of March 2023, the management team of Zim Laboratories includes the following individuals:<BR><BR>1. Anwar S Daud - Chairman & Managing Director<BR>2. Zulfiquar M Kamal - Director (Finance)<BR>3. Prakash Sapkal - Director (Operation)<BR>4. Niraj Dhadiwal - Director (Business Development)<BR>5. Kavita Loya - Non-Executive & Independent Director<BR>6. Padmakar Joshi - Non-Executive & Independent Director<BR>7. Piyush Nikhadi - Company Secretary & Compliance Officer<BR>8. Kamlesh Shende - Independent Director<BR>9. Kakasaheb Mahadik - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What is the bonus history of the Zim Laboratories?

Zim Laboratories has issued bonuses twice, with a 2:1 bonus on December 22, 2022, and a 1:1 bonus on October 4, 2018, reflecting the company's commitment to rewarding shareholders.

Zim Laboratories has a history of bonus issues that includes two significant events. The most recent bonus was a 2:1 bonus issue, which was announced with an ex-date of December 22, 2022. Prior to that, the company had a 1:1 bonus issue, which took place with an ex-date of October 4, 2018. This indicates that Zim Laboratories has actively engaged in rewarding its shareholders through bonus shares in the past.

Has Zim Laboratories declared dividend?

Zim Laboratories Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 19, 2019. However, the dividend yield is 0%, and total returns over various periods have shown mixed performance, including a significant decline of -55.21% over the last three years.

Zim Laboratories Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 19 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.67%, the dividend return was 0%, resulting in a total return of -15.67%.<BR><BR>Over the past year, the price return was -3.57%, with a dividend return of 0%, leading to a total return of -3.57%.<BR><BR>In the 2-year period, the price return was -4.62%, the dividend return was 0%, which resulted in a total return of -4.62%.<BR><BR>For the 3-year period, the price return was -55.21%, with a dividend return of 0%, culminating in a total return of -55.21%.<BR><BR>In the 4-year period, the price return was 14.87%, the dividend return was 0%, resulting in a total return of 14.87%.<BR><BR>Over the last 5 years, the price return was 47.63%, with a dividend return of 0%, leading to a total return of 47.63%.<BR><BR>Overall, while Zim Laboratories declared a dividend, the dividend yield remains at 0%, indicating no recent dividends have contributed to returns. The total returns over various periods show a mix of negative and positive performance, particularly a significant decline over the last three years.

Who are the peers of the Zim Laboratories?

Zim Laboratories' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab, Lyka Labs, Everest Organics, and SMS Lifesciences. Zim Laboratories has average management risk and growth, with a 1-year return of -13.95%, significantly lower than Everest Organics' 245.22%.

Peers: The peers of Zim Laboratories are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Brooks Lab., Lyka Labs, Everest Organics, and SMS Lifesciences.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Lyka Labs, while Average management risk is found at Zim Laboratories, Everest Organics, and SMS Lifesciences. Below Average management risk is noted at Brooks Lab. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Zim Laboratories, Torrent Pharma, Everest Organics, and SMS Lifesciences. Average growth is reported for Lyka Labs, and Below Average growth is noted for Brooks Lab. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Average capital structure is found at Zim Laboratories and SMS Lifesciences, and Below Average capital structure is observed at Brooks Lab. and Lyka Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 245.22%, while Zim Laboratories has the lowest at -13.95%. This indicates that Zim Laboratories' 1-year return is significantly lower than that of Everest Organics. Additionally, the six-month return is negative for Zim Laboratories, Cipla, Torrent Pharma, and Lyka Labs.

Is Zim Laboratories overvalued or undervalued?

As of March 17, 2025, Zim Laboratories is considered undervalued with a PE ratio of 40.02 and an attractive valuation grade, highlighted by a PEG ratio of 0.00 and a strong recent stock performance of 16.18% over one week, compared to 1.39% for the Sensex.

As of 17 March 2025, Zim Laboratories has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 40.02, an EV to EBITDA of 13.72, and a Price to Book Value of 1.93. These ratios suggest that the stock is trading at a reasonable valuation compared to its earnings and cash flow generation capabilities.<BR><BR>In comparison to its peers, Zim Laboratories stands out with a PEG ratio of 0.00, indicating potential growth at a low price relative to its earnings growth expectations. Notably, the company’s EV to EBITDA ratio is in line with industry standards, while its PE ratio is comparable to other players in the Pharmaceuticals & Biotechnology sector. Recent stock performance has also been strong, with a 1-week return of 16.18% compared to a 1.39% return for the Sensex, reinforcing the attractiveness of the current valuation.

What does Zim Laboratories do?

Zim Laboratories Ltd manufactures drug formulations and pre-formulation ingredients in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of 1,087 Cr and a net profit of 49 Cr, with a market cap of INR 563 Cr.

Overview:<BR>Zim Laboratories Ltd is engaged in the manufacturing of drug formulations and pre-formulation ingredients in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Zim Laboratories Ltd was incorporated in February 1984 as Zim Laboratories Private Limited and later became a Public Limited Company. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,087 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 49 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 563 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 45.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.45<BR>- Return on Equity: 4.82%<BR>- Price to Book: 2.22<BR><BR>Contact Details:<BR>- Address: Sadoday Gyan (Gr Floor), Opp NADT Nelson Square Nagpur Maharashtra : 440013<BR>- Tel: 91-712-2588070<BR>- Email: md@zimlab.in<BR>- Website: http://www.zimlab.in

Who are the top shareholders of the Zim Laboratories?

The top shareholders of Zim Laboratories include Anwar Daud with 27.37%, Elizabeth Mathew with 12.02%, and individual investors owning 47.78%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of Zim Laboratories include Anwar Daud, who holds the highest promoter stake at 27.37%. The highest public shareholder is Elizabeth Mathew, with a holding of 12.02%. Additionally, individual investors collectively own 47.78% of the company. There are also two foreign institutional investors (FIIs) that hold a very small percentage, specifically 0.01%. Notably, there are no pledged promoter holdings and no mutual funds involved in the shareholding.

How big is Zim Laboratories?

As of 24th July, Zim Laboratories Ltd has a market capitalization of 579.00 Cr, with net sales of 379.02 Cr and a net profit of 12.16 Cr reported in the latest four quarters. The company has shareholder's funds of 252.24 Cr and total assets of 472.02 Cr as of March 2025.

As of 24th July, Zim Laboratories Ltd has a market capitalization of 579.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, Zim Laboratories reported Net Sales of 379.02 Cr and a Net Profit of 12.16 Cr.<BR><BR>For the reporting period of March 2025, the company has Shareholder's Funds amounting to 252.24 Cr and Total Assets of 472.02 Cr.

Is Zim Laboratories technically bullish or bearish?

As of July 28, 2025, the trend is bullish due to strong daily moving averages and a bullish weekly MACD, despite some mixed signals from the weekly RSI and monthly KST.

As of 28 July 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish, with a strong daily moving average indicating positive momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The MACD is bullish on the weekly chart, supporting the overall bullish outlook, while the monthly MACD remains mildly bullish. Bollinger Bands show a bullish trend on the monthly, reinforcing the positive sentiment. The KST is bullish weekly but bearish monthly, indicating mixed signals. Overall, while there are some conflicting indicators, the prevailing trend is bullish, driven primarily by the daily moving averages and the weekly MACD.

How has been the historical performance of Zim Laboratories?

Zim Laboratories' historical performance shows fluctuating financial metrics, with net sales at 379.03 Cr in March 2025, a slight increase from the previous year but a decrease from March 2023. Key figures include a rise in operating profit to 49.50 Cr, while profit before tax and profit after tax fell to 18.01 Cr and 12.17 Cr, respectively.

Answer:<BR>The historical performance of Zim Laboratories shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Zim Laboratories reported net sales of 379.03 Cr for the year ending March 2025, a slight increase from 367.42 Cr in March 2024, but a decrease from 398.53 Cr in March 2023. The total operating income followed a similar pattern, reaching 379.03 Cr in March 2025. The raw material costs decreased to 155.00 Cr in March 2025 from 177.70 Cr in March 2024, while employee costs increased to 60.76 Cr from 53.34 Cr. Total expenditure, excluding depreciation, was 335.31 Cr in March 2025, up from 326.09 Cr in March 2024. Operating profit (PBDIT) was 49.50 Cr in March 2025, showing a rise from 46.51 Cr in March 2024, but down from 58.40 Cr in March 2023. Profit before tax decreased to 18.01 Cr in March 2025 from 23.64 Cr in March 2024, and profit after tax also fell to 12.17 Cr from 17.25 Cr. The earnings per share (EPS) dropped to 2.5 in March 2025 from 3.54 in March 2024. On the balance sheet, total assets increased to 472.02 Cr in March 2025 from 446.82 Cr in March 2024, while total liabilities rose to 472.02 Cr from 446.82 Cr. Cash flow from operating activities improved to 41.00 Cr in March 2025 from 16.00 Cr in March 2024, but the net cash outflow was -7.00 Cr in March 2025 compared to a net inflow of 3.00 Cr in March 2024.

When is the next results date for Zim Laboratories Ltd?

The next results date for Zim Laboratories Ltd is 11 February 2026.

The next results date for Zim Laboratories Ltd is scheduled for 11 February 2026.

Are Zim Laboratories Ltd latest results good or bad?

Zim Laboratories Ltd's latest results show a mixed performance, with a 22.49% increase in net sales and a return to profitability, but concerns remain due to compressed operating margins and low return on equity. Investors should exercise caution due to the company's underperformance relative to the broader pharmaceuticals sector and ongoing structural challenges.

Zim Laboratories Ltd's latest results present a mixed picture. On one hand, the company has shown a sequential recovery in its financial performance, with net sales increasing by 22.49% quarter-on-quarter to ₹108.66 crores and a return to profitability with a net profit of ₹4.40 crores, compared to a loss in the previous quarter. Year-on-year, net sales grew by 12.80% and net profit increased by 10.00%.<BR><BR>However, despite these positive indicators, there are significant concerns. The company's operating margin has compressed slightly compared to the previous year, and its return on equity (ROE) remains low at 6.55%, indicating poor capital efficiency. Additionally, Zim Laboratories has underperformed the broader pharmaceuticals sector and the market overall, with its stock declining 22.69% over the past year.<BR><BR>Overall, while there are signs of recovery, the underlying challenges related to cost management, operational efficiency, and capital returns suggest that the results are not entirely positive. Investors may need to approach the stock with caution, given the structural issues that persist despite the recent improvements.

Should I buy, sell or hold Zim Laboratories Ltd?

Why is Zim Laboratories Ltd falling/rising?

As of 05-May, Zim Laboratories Ltd's stock price is at 93.23, down 0.78% after three days of gains. Despite this short-term decline, the stock has shown strong performance over the past week and month, significantly outperforming the Sensex, while trading above its moving averages suggests a bullish trend.

As of 05-May, Zim Laboratories Ltd's stock price is currently at 93.23, reflecting a decrease of 0.73 or 0.78%. This decline comes after a period of three consecutive days of gains, indicating a trend reversal. Despite this recent drop, the stock has shown strong performance over various time frames, with a 10.10% increase over the past week and a substantial 39.84% rise over the past month, significantly outperforming the Sensex, which only increased by 0.17% and 5.04% in those respective periods.<BR><BR>Moreover, Zim Laboratories has been trading above its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bullish trend. Additionally, there has been a notable increase in investor participation, with delivery volume on May 4 rising by 299.02% compared to the 5-day average, indicating heightened interest in the stock.<BR><BR>However, today's performance has underperformed the sector by 1.23%, contributing to the stock's current decline. Overall, while the stock is experiencing a short-term fall, its longer-term performance metrics and increased trading activity suggest a complex situation where the stock has been strong but is currently facing a temporary setback.

Which are the latest news on Zim Laboratories?